PharmiWeb.com - Global Pharma News & Resources
05-Feb-2019

World Premature Ejaculation Therapeutics Market (2019-2024): A ~$3 Billion Opportunity, Led by Absorption Pharmaceuticals, Innovus Pharmaceuticals, Pfizer, and Plethora Solutions - ResearchAndMarkets.com

The "Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.

The report considers the present scenario of the global premature ejaculation therapeutics market and its market dynamics for the period 2019-2024. It covers a detailed overview of various market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes the leading companies and various other prominent companies operating in the market.

Market Dynamics

Growth Enablers

  • Increase in the Prevalence of PE and Other Chronic Diseases in Men
  • Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs
  • Low-effectiveness of Non-pharmacological PE Treatment
  • Presence of High Unmet Demand

Growth Restraints

  • Low Treatment Seeking Patient Pool
  • Presence of Alternative PF Treatment Methods
  • Clinical Trial Withdrawals/Terminations and Inactive Clinical Studies
  • Associated Adverse Effects of PE Drugs

Opportunities & Trends

  • Advances in PE Drug Formulation Technology
  • Emphasis on Clinical Progress of Love Hormone Receptor Antagonists
  • Increased Awareness Campaigns and Initiatives for PE Treatment

Market Segmentation

This market research report includes a detailed segmentation of the market by drug class, ROA, and geography.

The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period.

SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market. Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market.

The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period.

The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market. The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.

The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. North America occupied the largest market share in 2018, growing at a CAGR of around 9% during the forecast period.

The rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE, increases in cancers, especially prostate cancer is fueling the growth of the North American region in the global market. The high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs especially the off-label generic medicines, and low-cost OTC drugs are fueling the demand across the APAC region in the global premature ejaculation therapeutics market.

Key Vendor Analysis

The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market.

The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.

The major vendors in the global market are:

  • Absorption Pharmaceuticals
  • Innovus Pharmaceuticals
  • Pfizer
  • Plethora Solutions Holdings

Other prominent vendors include: Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis.

For more information about this report visit https://www.researchandmarkets.com/research/nqlj6c/world_premature?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190205005588/en/

Editor Details

Last Updated: 05-Feb-2019